Ambu A/S Net Assets
Ambu A/S net assets. Based on the latest financial reports, Ambu A/S (AMBU-B) has net assets worth Dkr6.17 Billion DKK (≈ $965.03 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr7.78 Billion ≈ $1.22 Billion USD) and total liabilities (Dkr1.61 Billion ≈ $251.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Ambu A/S (AMBU-B) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr6.17 Billion |
| % of Total Assets | 79.33% |
| Annual Growth Rate | 14.21% |
| 5-Year Change | 52.71% |
| 10-Year Change | 508.37% |
| Growth Volatility | 15.74 |
Net Assets of Ambu A/S (2002–2025)
Net assets of Ambu A/S from 2002 to 2025. This chart illustrates how Ambu A/S's net assets have evolved over time, based on quarterly financial data. Also explore AMBU-B net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Ambu A/S (2002–2025)
The table below shows the annual net assets of Ambu A/S from 2002 to 2025. For live market cap and overall valuation, see Ambu A/S (AMBU-B) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | Dkr6.04 Billion ≈ $944.22 Million |
+7.88% |
| 2024-09-30 | Dkr5.59 Billion ≈ $875.22 Million |
+3.73% |
| 2023-09-30 | Dkr5.39 Billion ≈ $843.77 Million |
+26.57% |
| 2022-09-30 | Dkr4.26 Billion ≈ $666.66 Million |
+7.82% |
| 2021-09-30 | Dkr3.95 Billion ≈ $618.32 Million |
+66.61% |
| 2020-09-30 | Dkr2.37 Billion ≈ $371.12 Million |
+8.71% |
| 2019-09-30 | Dkr2.18 Billion ≈ $341.39 Million |
+15.94% |
| 2018-09-30 | Dkr1.88 Billion ≈ $294.45 Million |
+47.15% |
| 2017-09-30 | Dkr1.28 Billion ≈ $200.11 Million |
+28.93% |
| 2016-09-30 | Dkr992.00 Million ≈ $155.21 Million |
-4.25% |
| 2015-09-30 | Dkr1.04 Billion ≈ $162.09 Million |
+21.31% |
| 2014-09-30 | Dkr854.00 Million ≈ $133.61 Million |
+28.04% |
| 2013-09-30 | Dkr667.00 Million ≈ $104.36 Million |
-1.64% |
| 2012-09-30 | Dkr678.11 Million ≈ $106.09 Million |
+16.94% |
| 2011-09-30 | Dkr579.86 Million ≈ $90.72 Million |
+3.25% |
| 2010-09-30 | Dkr561.60 Million ≈ $87.87 Million |
+17.09% |
| 2009-09-30 | Dkr479.62 Million ≈ $75.04 Million |
+6.11% |
| 2008-09-30 | Dkr452.01 Million ≈ $70.72 Million |
+8.09% |
| 2007-09-30 | Dkr418.18 Million ≈ $65.43 Million |
+6.93% |
| 2006-09-30 | Dkr391.07 Million ≈ $61.19 Million |
+12.01% |
| 2005-09-30 | Dkr349.14 Million ≈ $54.63 Million |
+9.06% |
| 2004-09-30 | Dkr320.14 Million ≈ $50.09 Million |
+8.85% |
| 2003-09-30 | Dkr294.12 Million ≈ $46.02 Million |
+3.58% |
| 2002-09-30 | Dkr283.94 Million ≈ $44.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ambu A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4999.8% over the analyzed period, indicating profitable operations and earnings retention.
Ambu A/S Net Assets Breakdown (September 2025)
Ambu A/S net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr5.86 Billion | 97.17% |
| Common Stock | Dkr135.00 Million | 2.24% |
| Other Comprehensive Income | Dkr36.00 Million | 0.60% |
| Total Equity | Dkr6.04 Billion | 100.00% |
Ambu A/S Competitors by Market Cap
The table below lists competitors of Ambu A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yongxing Special Stainless Steel Co Ltd
SHE:002756
|
$2.79 Billion |
|
Sinoma International Engineering Co Ltd
SHG:600970
|
$2.79 Billion |
|
Munters Group AB
ST:MTRS
|
$2.79 Billion |
|
KPJ Healthcare Bhd
KLSE:5878
|
$2.79 Billion |
|
Becle S.A.B. de C.V
MX:CUERVO
|
$2.79 Billion |
|
Shenzhen O-Film Tech Co Ltd
SHE:002456
|
$2.79 Billion |
|
Kingclean Electric Co Ltd
SHG:603355
|
$2.79 Billion |
|
Medical Properties Trust Inc
NYSE:MPW
|
$2.78 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ambu A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,594,000,000 to 6,035,000,000, a change of 441,000,000 (7.9%).
- Net income of 609,000,000 contributed positively to equity growth.
- Dividend payments of 101,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 211,000,000.
- Other factors increased equity by 144,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr609.00 Million | +10.09% |
| Dividends Paid | Dkr101.00 Million | -1.67% |
| Other Comprehensive Income | Dkr-211.00 Million | -3.5% |
| Other Changes | Dkr144.00 Million | +2.39% |
| Total Change | Dkr- | 7.88% |
Book Value vs Market Value Analysis
This analysis compares Ambu A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 44.50x to 3.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-09-30 | Dkr1.77 | Dkr78.60 | x |
| 2003-09-30 | Dkr1.83 | Dkr78.60 | x |
| 2004-09-30 | Dkr1.93 | Dkr78.60 | x |
| 2005-09-30 | Dkr1.48 | Dkr78.60 | x |
| 2006-09-30 | Dkr1.67 | Dkr78.60 | x |
| 2007-09-30 | Dkr1.77 | Dkr78.60 | x |
| 2008-09-30 | Dkr1.92 | Dkr78.60 | x |
| 2009-09-30 | Dkr2.03 | Dkr78.60 | x |
| 2010-09-30 | Dkr2.37 | Dkr78.60 | x |
| 2011-09-30 | Dkr2.44 | Dkr78.60 | x |
| 2012-09-30 | Dkr2.83 | Dkr78.60 | x |
| 2013-09-30 | Dkr2.83 | Dkr78.60 | x |
| 2014-09-30 | Dkr3.52 | Dkr78.60 | x |
| 2015-09-30 | Dkr4.19 | Dkr78.60 | x |
| 2016-09-30 | Dkr4.07 | Dkr78.60 | x |
| 2017-09-30 | Dkr5.26 | Dkr78.60 | x |
| 2018-09-30 | Dkr7.60 | Dkr78.60 | x |
| 2019-09-30 | Dkr8.82 | Dkr78.60 | x |
| 2020-09-30 | Dkr9.57 | Dkr78.60 | x |
| 2021-09-30 | Dkr15.61 | Dkr78.60 | x |
| 2022-09-30 | Dkr16.75 | Dkr78.60 | x |
| 2023-09-30 | Dkr20.69 | Dkr78.60 | x |
| 2024-09-30 | Dkr20.95 | Dkr78.60 | x |
| 2025-09-30 | Dkr22.60 | Dkr78.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ambu A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.09%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.09%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 1.27x
- Recent ROE (10.09%) is below the historical average (11.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 5.28% | 2.61% | 1.02x | 1.98x | Dkr-13.41 Million |
| 2003 | 8.84% | 4.59% | 1.02x | 1.89x | Dkr-3.40 Million |
| 2004 | 10.40% | 5.47% | 1.03x | 1.85x | Dkr1.27 Million |
| 2005 | 10.80% | 5.76% | 0.99x | 1.88x | Dkr2.78 Million |
| 2006 | 12.38% | 6.76% | 1.06x | 1.73x | Dkr9.31 Million |
| 2007 | 10.23% | 5.98% | 1.05x | 1.63x | Dkr959.10K |
| 2008 | 11.06% | 6.38% | 1.07x | 1.62x | Dkr4.81 Million |
| 2009 | 11.63% | 6.36% | 1.12x | 1.63x | Dkr7.80 Million |
| 2010 | 14.97% | 8.94% | 1.07x | 1.56x | Dkr27.90 Million |
| 2011 | 11.94% | 7.04% | 1.11x | 1.53x | Dkr11.23 Million |
| 2012 | 16.92% | 10.97% | 1.08x | 1.42x | Dkr46.90 Million |
| 2013 | 7.20% | 3.47% | 0.73x | 2.84x | Dkr-18.70 Million |
| 2014 | 17.68% | 9.53% | 0.77x | 2.40x | Dkr65.60 Million |
| 2015 | 14.67% | 8.05% | 0.84x | 2.18x | Dkr48.40 Million |
| 2016 | 25.20% | 12.00% | 0.88x | 2.39x | Dkr150.80 Million |
| 2017 | 23.53% | 12.78% | 0.94x | 1.95x | Dkr173.10 Million |
| 2018 | 17.91% | 12.93% | 0.62x | 2.25x | Dkr148.80 Million |
| 2019 | 14.53% | 11.24% | 0.62x | 2.09x | Dkr98.80 Million |
| 2020 | 10.16% | 6.76% | 0.72x | 2.08x | Dkr3.80 Million |
| 2021 | 6.25% | 6.15% | 0.70x | 1.45x | Dkr-148.20 Million |
| 2022 | 2.18% | 2.09% | 0.62x | 1.69x | Dkr-333.10 Million |
| 2023 | 3.12% | 3.52% | 0.70x | 1.27x | Dkr-371.30 Million |
| 2024 | 4.20% | 4.36% | 0.75x | 1.28x | Dkr-324.40 Million |
| 2025 | 10.09% | 10.09% | 0.79x | 1.27x | Dkr5.50 Million |
Industry Comparison
This section compares Ambu A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,252,176,600
- Average return on equity (ROE) among peers: -5.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ambu A/S (AMBU-B) | Dkr6.17 Billion | 5.28% | 0.26x | $2.79 Billion |
| ChemoMetec A/S (CHEMM) | $43.23 Million | 0.80% | 0.18x | $1.69 Billion |
| Demant A/S (DEMANT) | $5.58 Billion | 23.75% | 1.01x | $12.08 Billion |
| GN Store Nord (GN) | $5.54 Billion | 5.79% | 0.48x | $2.51 Billion |
| Scandinavian Medical Solutions AS (SMSMED) | $82.67 Million | 0.03% | 1.49x | $11.91 Million |
| ViroGates A/S (VIRO) | $8.98 Million | -60.13% | 0.34x | $10.96 Million |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as… Read more